论文部分内容阅读
Non-selective beta-blockers are the mainstay of medical therapy for portal hypertension in liver cirrhosis.Inhibitors of phosphodiesterase-5(PDE-5-inhibitors)reduce portal pressure in the acute setting by>10%which may suggest a long-term beneficial eff